Date: 2014-07-21
Type of information: Recruitment of the first patient
phase: 1-2a
Announcement: recruitment of the first patient
Company: Metamax (Russia)
Product: MM-D37K
Action
mechanism: MM-D37K is a chimeric peptide based on the use of CPP (cell penetrating peptide) for intracellular delivery of target antitumor peptides that inhibit proliferation and activate apoptosis. Using such CPP transport sequence allows the chimeric peptide to penetrate through the cell membrane with high speed and efficiency and possibly to cross blood-brain barrier. One functional part of the peptide MM-D37K is the sequence of endogenous intracellular peptide p16, inhibitor of cyclin-dependent kinases (CDK). The loss of CDK inhibitory function is typical for a broad range of malignant diseases includung colorectal, gastric and pancreactic cancers. This chimeric peptide activates apoptosis in cancer cells using cyclin kinase inhibition mechanism. Preclinical studies results demonstrated a good safety profile of the peptide and its significant antitumor effect in animal cancer models.
Disease: advanced solid malignancies, including glioblastoma and gastrointestinal tumors
Therapeutic area: Cancer - Oncology
Country: Russia
Trial
details: The trial will enroll 21 patients with advanced solid malignancies, including glioblastoma and gastrointestinal tumors. It is being conducted at some of the major Russian oncology centers with a strong 1/2a Phase cancer clinical trials background. The main goal of the trial is to investigate safety, tolerability and pharmacokinetics of multiple use of the study drug in different dose levels, to assess the tumor response to the therapy. Additionally the trial will evaluate the correlation of the therapeutic effect with biomarker levels to select patient populations for further clinical trials of MM-D37K.
Latest
news: * On July 21, 2014, Maxwell Biotech Venture Fund\'s portfolio company MetaMax announced enrollment of first patients in a Phase 1/2a clinical trial of its lead anticancer drug MM-D37K. Following approval by the Russian Ministry of Health, Russian biotechnology company MetaMax will begin the trial of its lead anticancer compound MM-D37K. MetaMax is financed by Maxwell Biotech Venture Fund, set up with the participation of RVC. The trial will enroll 21 patients with advanced solid malignancies, including glioblastoma and gastrointestinal tumors.
